SEC Comment Letter for Anixa Biosciences Inc (ANIX) (CIK 0000715446) (ANIX) — Jun 13, 2014
Anixa Biosciences Inc (ANIX) (CIK 0000715446)
Date: June 13, 2014 · CIK: 0000715446 · Accession: 0000000000-14-030136
AI Filing Summary & Sentiment
File numbers found in text: 000-11254
Show Raw Text
June 12 , 2014 Via E -Mail Robert A. Berman Chief Executive Officer CopyTele, Inc. 900 Walt Whitman Road Melville, New York 11747 Re: CopyTele, Inc. Preliminary Proxy Statement on Schedule 14 A Filed on June 3, 2014 File No. 000-11254 Dear Mr. Berman : We have reviewed your filing an d have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter within ten business days by amending your filing, by providing the requested information, or by advising us when you will provide the requested response. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your filing and the information you provide in response to these comments, we may have additional comments. Proposal 4 Name Change Proposal, page 42 1. Please tell us, and e xpand your disclosure to reference , what in your bylaws, articles of incorporation or other governing documents permits you to change your corporate name to another name to be selected by you at a later dat e without informing shareholders of the new name . In your response letter, explain how the authority the board seeks with respect to a future selection of a corporate name is consistent wi th Delaware law and the proxy rules. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable Exchange Act rules require. Since the company and its management are Robert A. Berman CopyTele, Inc. June 12, 2014 Page 2 in possession of all facts relating to a company’s disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made. In responding to our comments, please provide a written statement from the company acknowledging that: the company is responsible for the adequacy and accuracy of the disclosure in the filing; staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Please contact Ji Kim, Attorney -Advisor, at (202) 551 -3579 or, in her absence, the undersigned at (202) 551 -3457 with any questions. Sincerely, /s/ Maryse Mills -Apenteng Maryse Mills -Apenteng Special Counsel